NIAID awards Rho $16.5m yearly CRO contract

By Fiona BARRY contact

- Last updated on GMT

The NIAID contract pays Rho approximately $16.5m per year for seven years, with an extra $6.8m in the first year.
The NIAID contract pays Rho approximately $16.5m per year for seven years, with an extra $6.8m in the first year.

Related tags: Immune system

US contract research organisation Rho has won its largest federal contract with the National Institute of Allergy and Infectious Diseases (NIAID).

The North Carolinan CRO, which provides clinical services for commercial and government markets, will perform statistical analysis, bioinformatics, and clinical data management services to NIAID’s Division of Allergy, Immunology and Transplantation (DAIT).
DAIT has large clinical research needs in asthma and allergic diseases, autoimmune diseases, and transplantation.
The contract is worth approximately $16.5m per year for seven years, with an extra $6.8m in the first year.

Multiple PI structure

The scope of the project means Rho will set up five employees as principle investigators (PIs): Ronald Helms, Rho chair and head PI for the NIAID contract; Karen Kesler, senior research scientist and leadership group PI; Samuel Arbes, seior research scientist and group leader for the Asthma and Allergic Diseases Group; David Ikle, senior statistical scientist and group leader for the Transplantation Group; and Lynette Keyes-Elstein, senior statistical scientist and group leader for the Autoimmune Diseases Group. Michelle Walter, senior project director, will also help with day-to-day management of the research.

Additionally, day-to-day management will be provided by Michelle Walter, M.S., Senior Project Director.
The project was funded by federal grant number UM2-AI117870 from NIAID.

This is the largest NIAID contract for Rho, but not the first. In 2008, it signed an almost $39m deal to provide data management and safety services to the Institute’s Immune Tolerance Network.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars